You have 9 free searches left this month | to do more

177lu-psma-617

177lu Psma 617 is a drug used to treat Prostate Cancer and Prostatic Neoplasms. 177lu Psma 617 is being actively studied in 9 studies; no studies for this drug have been completed so far.

Top SponsorsTop SitesTop Investigators
EndocyteNovartis Investigative Site
Novartis PharmaceuticalsPeter MacCallum Cancer Centre
Peter MacCallum Cancer Centre, AustraliaTulane Cancer Center
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
W
Terminated
  • Prostate Cancer
  • 177Lu-PSMA-617
  • +2 more
  • New York, New York
    Weill Cornell Medical College
2021-07-29
Jul 29, 2021
A
Available
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
2021-06-10
Jun 10, 2021
M
Recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • Stereotactic Body Radiotherapy (SBRT)
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
2021-10-04
Oct 4, 2021
W
Active, not recruiting
  • Prostate Cancer
  • New Orleans, Louisiana
  • +1 more
2021-05-05
May 5, 2021
P
Recruiting
  • Prostatic Neoplasms
  • 177Lu-PSMA-617
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
2020-08-05
Aug 5, 2020
R
Recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • Amsterdam, Netherlands
  • +3 more
2021-10-17
Oct 17, 2021
E
Terminated
  • Metastatic Castration Resistant Prostate Cancer
  • 177Lu-PSMA-617
  • Los Angeles, California
  • +1 more
2021-03-01
Mar 1, 2021
C
Recruiting
  • Prostate Cancer
  • Vancouver, British Columbia, Canada
  • +2 more
2021-11-08
Nov 8, 2021
N
Recruiting
  • Prostatic Neoplasms
  • 177Lu-PSMA-617
  • +3 more
  • New Orleans, Louisiana
  • +37 more
2021-11-17
Nov 17, 2021
P
Recruiting
  • Metastatic Hormone Naive Prostate Cancer
  • Sydney, New South Wales, Australia
  • +4 more
2021-01-07
Jan 7, 2021
E
Active, not recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • Best supportive/best standard of care
  • Scottsdale, Arizona
  • +87 more
2021-07-26
Jul 26, 2021